Table 1 Basic clinical and laboratory data of study population
From: Cytokine expression profiles in white blood cells of patients with small fiber neuropathy
Patients (n = 52) | Controls (n = 21) | |
|---|---|---|
Age [years] (range) | 54a (19–73) | 48a (22–66) |
Gender (F/M) | 32/20 | 13/8 |
Time since diagnosis [years] (range) | 0.25a (< 1 month-12) | NA |
Pain duration [years] | 3.25a (< 1 month-24) | NA |
Assumed etiology of SFN | NA | |
Determined (In some patients ≥ 1 pathological finding was present, thus, the sum exceeds 100%) | 22/52 (42%) | |
Diabetes or impaired glucose tolerance | 22/52 (42%) | |
Vitamine B12 deficiency | 2/52 (4%) | |
Hereditary | 5/52 (10%) | |
Thyroid dysfunction | 6/52 (12%) | |
Idiopathic | 30/52 (58%) | |
Abnormal results in routine laboratory tests b (In some patients ≥ 1 pathological finding was present) | 9/52 (17%) | Not investigated |
Leucocytosis (Ref.: 5–10*103/µl) | 2/52 (4%) | |
Leucopenia (Ref.: 5–10*103/µl) | 1/52 (2%) | |
Creatinine (Ref.: 0–0.95 mg/dl) ↑ | 2/52 (4%) | |
CRP (Ref.: 0–0.5 mg/dl) ↑ | 2/52 (4%) | |
Gamma GT (Ref.: < 40 U/l) ↑ | 1/52 (2%) | |
Abnormal results in extended laboratory tests c (In some patients ≥ 1 pathological finding was present) | 28/52 (51%) | NA |
HbA1c (Ref.: ≤ 6.1%) ↑ | 7/52 (13%) | |
Vitamin B12 (Ref.: ≥ 197 pg/ml) ↓ | 2/52 (4%) | |
TSH (Ref.: 0.3–4.0 mlU/l) ↑ | 1/52 (2%) | |
TSH (Ref.: 0.3–4.0 mlU/l) ↓ | 1/52 (2%) | |
Detected autoantibodies (antinuclear antibodies, extractable nuclear antigen antibodies, anti-neutrophil cytoplasmic antibodies) | 2/52 (4%) | |
Pathological oGTT (2 h glucose level ≤ 140 mg/dl) | 15/52 (29%) | NA |
Pain distribution | NA | |
Acral | 15/52 (29%) | |
Generalized | 22/52 (42%) | |
Both | 15/52 (29%) | |
Pain intensity [NRS] (range) | NA | |
Current pain intensity | 4a (0–8) | |
Maximum pain intensity | 8a (3–10) | |
Mean pain intensity | 5a (0–8) | |
Female | 5a (0–8) | |
Male | 4a (0–8) | |
Signs of small fiber impairment in neurological examination | 30/52 (58%) | None |
Thermal hypoesthesia | 13/52 (25%) | |
Hypo-/hyperalgesia | 15/52 (29%) | |
Allodynia | 4/52 (8%) | |
Dysesthesia/paresthesia | 7/52 (13%) | |
Additional symptoms | NA | |
Gastrointestinal symptoms | 3/52 (5%) | |
Obstipation | 1/52 (2%) | |
Diarrhea | 2/52 (4%) | |
Autonomic symptoms | 29/52 (56%) | |
Hypo-/hyperhidrosis | 27/52 (52%) | |
Sexual dysfunction | 7/52 (13%) | |
Impairment of micturition | 6/52 (12%) | |
Repetitive syncope | 0/52 (0%) |